Connor, Clark & Lunn Investment Management Ltd. Biomarin Pharmaceutical Inc Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 116,257 shares of BMRN stock, worth $7.52 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

116,257

Holding current value

$7.52 Million

% of portfolio

0.04%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	BUY	$69.02 - $93.84 $8.02 Million - $10.9 Million	116,257 New	116,257 $8.17 Million
Q3 2023 Nov 13, 2023	SELL	$85.07 - $94.48 $770,734 - $855,988	-9,060 Reduced 63.13%	5,292 $468,000
Q2 2023 Aug 10, 2023	SELL	$86.68 - $100.3 $18.7 Million - $21.7 Million	-216,114 Reduced 93.77%	14,352 $1.24 Million
Q1 2023 May 09, 2023	SELL	$87.74 - $117.27 $7.67 Million - $10.3 Million	-87,430 Reduced 27.5%	230,466 $22.4 Million
Q4 2022 Feb 10, 2023	BUY	$80.93 - $108.63 $9.43 Million - $12.7 Million	116,511 Added 57.85%	317,896 $32.9 Million
Q3 2022 Nov 10, 2022	SELL	$82.16 - $96.94 $3.76 Million - $4.44 Million	-45,816 Reduced 18.53%	201,385 $17.1 Million
Q2 2022 Aug 05, 2022	BUY	$71.48 - $86.85 $6.53 Million - $7.93 Million	91,298 Added 58.56%	247,201 $20.5 Million
Q1 2022 May 12, 2022	BUY	$74.28 - $92.69 $10.6 Million - $13.2 Million	142,606 Added 1072.47%	155,903 $12 Million
Q4 2021 Feb 10, 2022	SELL	$71.72 - $91.47 $4.16 Million - $5.31 Million	-58,034 Reduced 81.36%	13,297 $1.18 Million
Q3 2021 Nov 12, 2021	BUY	$74.77 - $85.47 $3.79 Million - $4.33 Million	50,623 Added 244.46%	71,331 $5.51 Million
Q2 2021 Aug 12, 2021	BUY	$75.51 - $84.79 $974,834 - $1.09 Million	12,910 Added 165.56%	20,708 $1.73 Million
Q1 2021 May 13, 2021	SELL	$74.73 - $90.69 $1.31 Million - $1.6 Million	-17,594 Reduced 69.29%	7,798 $589,000
Q4 2020 Feb 16, 2021	BUY	$72.61 - $90.2 $1.18 Million - $1.47 Million	16,284 Added 178.79%	25,392 $2.23 Million
Q3 2020 Nov 12, 2020	BUY	$71.87 - $131.03 $99,683 - $181,738	1,387 Added 17.96%	9,108 $693,000
Q2 2020 Aug 13, 2020	SELL	$79.55 - $124.22 $85,834 - $134,033	-1,079 Reduced 12.26%	7,721 $952,000
Q4 2019 Feb 12, 2020	BUY	$64.27 - $86.37 $40,168 - $53,981	625 Added 7.65%	8,800 $744,000
Q3 2019 Nov 13, 2019	BUY	$67.4 - $85.11 $193,775 - $244,691	2,875 Added 54.25%	8,175 $551,000
Q2 2019 Aug 07, 2019	BUY	$80.35 - $93.9 $425,854 - $497,670	5,300 New	5,300 $454,000
Q2 2018 Aug 02, 2018	SELL	$76.01 - $99.03 $478,863 - $623,889	-6,300 Closed	0 $0
Q1 2018 May 14, 2018	SELL	$77.67 - $92.63 $54,369 - $64,841	-700 Reduced 10.0%	6,300 $511,000
Q4 2017 Feb 09, 2018	SELL	$80.76 - $95.13 $991,329 - $1.17 Million	-12,275 Reduced 63.68%	7,000 $624,000
Q3 2017 Nov 14, 2017	BUY	$80.6 - $94.95 $1.34 Million - $1.57 Million	16,575 Added 613.89%	19,275 $1.79 Million
Q2 2017 Aug 14, 2017	BUY	N/A	2,700	2,700 $245,000

Others Institutions Holding BMRN

# of Institutions

638

Shares Held

178M

Call Options Held

2.01M

Put Options Held

1.28M

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account

Connor, Clark & Lunn Investment Management Ltd. Biomarin Pharmaceutical Inc Transaction History